Filings

Recent filings

Filing	Date
Zealand interim report for the first nine months of 2015 (un-audited): Financial results on target with significant pipeline progress	5 Nov 2015
Zealand increases its share capital after exercise of employee warrants and announces trading in the company’s shares and related securities by executives and their related parties	4 Nov 2015
Zealand reports Lyxumia® royalty revenue for Q3 2015 and that Sanofi confirms expected next steps in the US regulatory process	29 Oct 2015
Notice of Zealand’s Interim Report for the first 9 months of 2015 and invitation to related conference call	27 Oct 2015
Financial Calendar for 2016	23 Oct 2015
Zealand to attend three international Investor Healthcare Conferences and host Capital Markets Days in November	22 Oct 2015
Zealand to host Capital Markets Days in New York City and Copenhagen in November	14 Oct 2015
Zealand meets development milestone in collaboration with Boehringer Ingelheim	9 Oct 2015
Zealand announces total number of shares and voting rights in the company as of 30 September 2015	30 Sept 2015
Zealand increases its share capital after exercise of employee warrants	26 Sept 2015
Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome	17 Sept 2015
Sanofi has announced the successful completion of LixiLan-L, the second pivotal Phase III trial with LixiLan to demonstrate positive results	14 Sept 2015

ZEALAND PHARMA